BioSpace News Archive

Savillex, a leading high-performance container and containment solutions provider, announced the launch of a new PETG Square Media Bottle product line under its Purillex® brand.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”) today announced preliminary unaudited financial highlights for the fourth quarter and full-year 2023, provided financial guidance for the first quarter and full-year 2024, and announced completion of patient enrollment in its post-market study, TONE.

U.S. Orthopaedic Partners, a prominent, multi-state orthopaedic care platform, proudly announces the appointment of Stephen G. Holtzclaw, MD, MBA, as its new chief executive officer, effective January 1, 2024.

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by UCB to dispense ZILBRYSQ®, a new FDA-approved therapy for the treatment of adults with gMG who are anti-AChR antibody positive.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) announces that Dr. Michael Gross has retired from the Company’s Board of Directors (the “Board”) to focus on other business interests.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company”), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it successfully tested a new formulation of its ACCUM-002TM Dimer CDCA-SV40 commonly named “AccuTOX®", as an anticancer treatment for lung-established tumors.

Chiesi Global Rare Diseases today announced the publication of data from the Phase 3 BALANCE study that demonstrate ELFABRIO® (pegunigalsidase alfa-iwxj) was generally well tolerated and comparable to agalsidase beta based on estimated glomerular filtration rate (eGFR) decline over two years in adults with Fabry disease with previous agalsidase beta treatment and deteriorating renal function.

The family-owned MedTech company KARL STORZ announces the acquisition of innovative software manufacturer Innersight Labs Ltd., headquartered in London.

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) (“Lykos”) announced that PLOS ONE has published the first comparison of the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe post-traumatic stress disorder (“PTSD”).

Inventiva announced the drawdown of the second tranche of €25 million of the unsecured loan agreement executed with the European Investment Bank on May 16, 2022 with a maturity date on or about January 18, 2027.